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Abstract We have investigated the e¡ects of alternative splic-
ing on transcripts encoding membrane proteins in 1001 human
genes. Out of a total of 464 alternatively spliced genes encoding
single-pass transmembrane (TM) proteins, in 188 we observed a
splice form that speci¢cally removed the TM domain, producing
a soluble protein isoform. For example, in syndecan-4, the new
alternative splice form closely parallels the proteolytic ectodo-
main shedding previously shown in this protein, and recognized
as an important regulatory mechanism of receptor function.
While many of the soluble isoforms produced by alternative
splicing have already been validated, most are novel, and in
57 genes showed a statistically signi¢cant association (P-val-
ue6 0.01) with a speci¢c tissue.
, 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Alternative splicing is a well-known mechanism for modu-
lating gene function in di¡erent tissues and cellular states.
Previously believed to occur in only 5^15% of human genes,
it has recently been found to be widespread in the human and
other genomes, and according to studies of expressed se-
quence tags (ESTs) is observed in around 30^60% of human
genes [1^7]. Moreover, more than 80% of the alternative splice
forms identi¢ed in EST data appear to be novel; that is, they
have not previously been reported in existing mRNA sequence
databases (for example, in GenBank). Therefore identi¢cation
and analysis of these alternatively spliced isoforms have re-
ceived great interest in the past several years [8^11], in partic-
ular their impact on protein function [12], for example, glob-
ular protein domains [13].
One major question about alternative splicing is its impact
on membrane protein function. It is estimated that 20^30% of
all genes in most genomes encode integral membrane proteins
[14^16]. Most of the integral membrane proteins contain
membrane-spanning hydrophobic K-helices which are inserted
into the membrane lipid bilayer [17] and are generally classi-
¢ed into single-pass and multi-pass membrane proteins ac-
cording to their number of transmembrane (TM) segments.
They play a variety of crucial biological roles including signal
transduction, transportation, energy metabolism and cell ad-
hesion [18^21], participate in many important forms of regu-
lation, and are the major targets of therapeutic drugs [22^24].
Extensive biochemical studies have demonstrated that one
way to modulate membrane protein function is to release such
a protein from its membrane anchorage, turning it into a
soluble form [25]. Proteolytic cleavage has been shown to be
a widespread mechanism for generating soluble fragments of
membrane proteins [26,27]. Cleavage can occur in the extra-
cellular region (termed ‘ectodomain shedding’), releasing it
from the membrane [28], or in the intracellular region (termed
regulated intracellular proteolysis, RIP) [29]. These two pro-
cesses are known to a¡ect a wide range of membrane proteins
such as Notch [30], Erb-B4 [31], and TGF-K [32]. Almost all
types of membrane proteins have known examples of these
proteolytic regulatory events [28]. The resulting soluble pro-
tein fragments can act as di¡usible signals that agonize or
antagonize the function of the membrane-bound form, or
can transmit a signal to another location [33^35].
In this paper we analyze the e¡ects of alternative splicing on
membrane protein anchoring. There is some precedent for
considering this to be a biologically interesting question.
There are several examples of known membrane-anchored
proteins (CD46, cadherin-7, and IL4 receptor) where it has
been shown that alternative splicing removes the exonic se-
quence coding the TM domain, generating a soluble form of
the protein [36^38] that functions di¡erently from the mem-
brane-bound form.
To analyze the e¡ects of alternative splicing on membrane
anchoring in a large sample of the human proteome, we con-
structed a database of alternatively spliced protein isoforms
(ASP) based on our analysis of human expressed sequences,
generating a collection of 13 384 isoforms for 4422 human
genes [39,40]. We used this database to identify genes where
alternative splicing removed a putative single-pass TM do-
main, producing a soluble isoform of a protein that is nor-
mally membrane-anchored. Our results demonstrate that this
form of regulation is widespread, is present in a surprisingly
large fraction of membrane proteins, and appears to be anal-
ogous to proteolytic cleavage in its functional impact. This
database should be of interest to researchers studying regula-
tion of membrane protein function, and hopefully will stim-
ulate many new experimental studies of these novel protein
isoforms.
2. Materials and methods
We identi¢ed alternative splicing events in human genes as previ-
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ously described [6], using NCBI’s January 2002 draft human genomic
sequence [5] and UniGene human EST data [41] downloaded in Jan-
uary 2002. Individual exons were identi¢ed by their start and end
positions in the genomic sequence; individual splices were identi¢ed
by their 5P and 3P splice site positions in the genomic sequence. A
transcript was de¢ned as a list of exons and a list of associated splices
connecting them. The major transcript was identi¢ed as the transcript
with largest number of consistent expressed sequence evidence. The
longest open reading frame (ORF) was identi¢ed in each candidate
transcript.
The set of transcripts was ¢ltered by a variety of criteria: (1) Only
major^minor isoform pairs resulting in a change to the protein prod-
uct were retained. (2) No transcripts incorporating non-consensus
splice sites were permitted. (3) The transcript’s longest ORF must
be full-length, i.e. begin with AUG and end with a STOP codon.
(4) Minor-form protein products must have at least 50% identity to
the major form (that is, no more than half of the major-form protein
sequence can be changed or removed), and a minimum length of 50
amino acids. This produced a subset (ASP database) of 13 384 protein
isoforms in 4422 human genes. Potential non-sense-mediated decay
(NMD) targets in ASP were identi¢ed by checking for a STOP codon
located over 50 bp upstream of the last exon^exon junction [42]. Full
details and validation results of the isoform generation procedure
have been presented elsewhere [40].
We have also performed a number of tests to assess the transcript
sequences for the 188 genes described in this paper. First, we tested
whether the region predicted to be a TM domain genuinely exists in a
human-curated protein sequence from the SwissProt database. Out of
73 cases where our data could be compared with a SwissProt entry
with the same gene symbol, in 64 cases our protein sequence was an
exact match to the SwissProt entry, and in six cases our sequence was
somewhat shorter than the SwissProt sequence, typically due to lack
of EST coverage over the full length of the gene. However, in all six of
these cases the region predicted to be a TM domain was matched by
the SwissProt sequence. Finally, in three cases the TM isoform was
novel. Thus, the relevant protein sequence region was validated in 70
of 73 test cases (96%). Next, we assessed whether the TM domain was
really removed by alternative splicing, using a conservative criterion
that at least 70% of the amino acids composing the TM domain must
be deleted by an observed alternative splice. Out of the 188 cases, 159
deleted at least this fraction of the residues of the TM region. Thus,
the data indicate that in at least 85% of the cases we report, alter-
native splicing genuinely removes the possibility of a TM region from
the protein sequence.
We used the program TMHMM to identify putative TM regions in
ASP protein isoforms. TMHMM uses a hidden-Markov model ap-
proach to predict TM protein topology, and is evaluated as having the
best overall performance by several recent independent tests [16,43^
45]. Protein isoform sequences were submitted to the THHMM 2.0
server, and putative TM regions in each isoform were identi¢ed. Us-
ing this approach, we identi¢ed the set of genes encoding single-pass
TM proteins (group A), and the subset that also had alternative splice
forms lacking a TM region (group B).
We tested the accuracy of TMHMM for a random sample of 25
single-pass membrane proteins and a random sample of 25 soluble
proteins in human from SwissProt. Among the 25 single-pass mem-
brane proteins, TMHMM missed the TM region in two proteins and
predicted an additional TM region in one protein, yielding the correct
result in 22 single-pass membrane proteins out of the 25 proteins
tested (88%). The boundaries predicted by TMHMM agree well
with the human-curated TM annotations in SwissProt (see Appendix
2, table B1). Among the 25 soluble proteins, TMHMM made a single
false positive prediction (Appendix 2, table B2), yielding an accuracy
of 96%.
We used Gene Ontology (downloaded in August 2002) to check
whether the production of soluble forms by alternative splicing is
more frequent in certain type of alternatively spliced TM proteins,
using a similar approach as described before [46,47]. We compared
group B with group A to look for GO keywords t found at much
higher frequency in group B than group A. We de¢ne:
N= total number of genes in group A annotated by GO
n=number of genes in group A annotated by GO key-
word t
M= total number of genes in group B annotated by GO
m=number of genes in group B annotated by GO key-
word t
and calculated the enrichment ratio of GO keyword t in group B, and
its P-value according to the hypergeometric distribution:
Enrichment ratio ¼ m=M
n=N
P-value ¼
Xn
k¼m
M
k
 !
N3M
n3k
 !
N
n
 !
If the enrichment ratio is less than 1, then the P-value is calculated as:
P-value ¼
Xm
k¼0
M
k
 !
N3M
n3k
 !
N
n
 !
3. Results and discussion
3.1. Identi¢cation of alternative splice forms altering membrane
anchoring
We searched for TM domains in protein isoform sequences
using the program TMHMM [16,43^45]. TMHMM identi¢ed
TM domains in 1001 of the 4422 human genes in our dataset
(22.6%). In 533 of these genes (53.2%) alternative splicing
changed the number of TM domains (Fig. 1). Out of a total
of 464 genes coding single-pass membrane proteins (with a
single TM domain) in our dataset, 188 had isoforms that
produced a soluble protein isoform (no predicted TM domain
according to TMHMM; we will refer to this as ‘TM remov-
al’). Thus alternative splicing frequently converted single-pass
TM proteins to soluble forms (40.5% of the cases in our data-
set). In 117 out of the 188 UniGene clusters (62.2%) TM
regions are encoded by a cassette exon which can be removed
by alternative splicing. Among genes with multiple evidence
for each isoform (that is, each alternative splice form is sup-
ported by an mRNA or at least two ESTs), we found soluble
isoforms in 130 genes out of 342 alternatively spliced single-
TM genes (38.0%)
Fig. 1. Removal of TM domains by alternative splicing. A histo-
gram of the number of genes in the ASP dataset encoding 1, 2 or
more predicted TM domains. The ¢lled portion of each bar (red) in-
dicates the number of genes in which a TM domain was removed
by alternative splicing.
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Removal of TM domains by alternative splicing occurred
more frequently than expected by random chance. De¢ning
‘TM deletion’ as meaning that at least 70% of the residues of
the TM domain were deleted by alternative splicing, we ob-
served TM deletion in 159 of the 464 single-TM genes in our
dataset (34%). By contrast, under a random model (in which
TM domains were repositioned randomly in the protein se-
quence), only 98 TM deletions occurred, indicating that the
observed rate of TM deletion is signi¢cantly higher than ran-
dom (P-value of 5U1036 by Fisher’s Exact Test), consistent
with a similar ¢nding for globular protein domains [13]. In
103 genes (64.8%), the region removed by alternative splicing
extended not further than 80 amino acids from the plasma
membrane, including 60 (37.7%) within 40 amino acids to
the plasma membrane.
In many cases, the TM removal identi¢ed by our analysis
from EST data can be directly validated by human-curated
mRNA sequences from GenBank. For 57 of these genes
(30.3% of the 188 single-TM genes in our dataset), we found
full-length mRNA sequences in GenBank supporting both the
membrane-anchored isoform and also the soluble isoform. We
also performed extensive validation of our protein isoform
sequences and TM domain identi¢cation and removal (see
Section 2).
Consistent with previous genomics studies of alternative
splicing, the majority of alternative splice forms we identi¢ed
appear to be novel [1^7] ; that is, they have not previously
been reported in any mRNA deposited in GenBank. For
the 166 genes in which at least one of the membrane-anchored
form or soluble form has full-length mRNA evidence, the
soluble form is novel in 90 genes, but the membrane-anchored
form is novel in only 19 genes.
3.2. Alternative splicing of syndecan-4 mimics proteolytic
ectodomain shedding
Our analysis also identi¢ed many novel soluble isoforms of
known TM proteins with interesting functional implications.
For example, we identi¢ed a novel isoform of syndecan-4,
supported by three ESTs (Fig. 2). Syndecan-4 belongs to a
family of TM heparan sulfate proteoglycans (HSPGs). It has
the ability to bind to a variety of ligands including extracel-
lular matrix components, growth factors, cell adhesion mole-
cules, cytokines, proteinases, etc. [48^50]. Syndecan-4 has
been shown to undergo ectodomain shedding. The proteolytic
cleavage at the extracellular region of syndecan-4 releases a
soluble form of syndecan-4 from the membrane which retains
its ligand binding ability [51,52]. The ectodomain of syndecans
has been suggested to play a role in a variety of biological
processes. Ectodomain shedding of syndecan-1 and -4 is ac-
celerated during injury and in£ammation, generating a soluble
fragment which can facilitate signaling by acting as a co-re-
ceptor; the soluble fragment is also reported to antagonize or
agonize FGF-2 in di¡erent situations [28]. While the full-
length syndecan-4 mRNA has ¢ve exons [53] and most of
the ESTs in its UniGene cluster match this canonical gene
structure, we detected an alternative splice in three ESTs
(Hs#S3789360 from epithelioid carcinoma cell line;
Hs#S541656 from pregnant uterus; Hs#S604747 from pooled
human melanocyte, fetal heart, and pregnant uterus) which
splice from the fourth exon to a new exon located between
the fourth exon and last exon in syndecan-4 mRNA. The new
exon (which we call exon V-b) contains an in-frame STOP
codon. The new syndecan-4 isoform supported by three
ESTs truncates the protein’s C-terminus, removing the TM
domain coded by the last exon (exon V-a in Fig. 2). It is
striking that the alternative splice form of syndecan-4 encodes
a soluble isoform that is closely analogous to the soluble form
of syndecan-4 known to be produced by ectodomain shedding
[51,52].
3.3. Functional impact of TM domain removal by alternative
splicing
TM removal by alternative splicing showed a notable asym-
metry in our dataset: membrane-anchored forms were more
likely to be the more common, ubiquitous isoform, while the
soluble forms were often localized to a speci¢c tissue. Using
previously described methods for calculating the statistical
con¢dence of apparent tissue speci¢city [54], we evaluated
both the membrane-bound and soluble isoforms of all 188
genes in our TM removal set. In 67 genes (36%) one or
both of the isoforms showed signi¢cant tissue speci¢city (P-
value6 0.01), suggesting that regulation of membrane-anchor-
ing is an important category of tissue-speci¢c alternative splic-
ing. Moreover, in 57 out of these 67 genes (85.1%), the soluble
isoform was tissue-speci¢c by these criteria, whereas the mem-
brane-bound isoform was tissue-speci¢c in only 29 genes
(43.3%). For example, we identi¢ed a soluble isoform for
HLA-DMB (Hs.1162) which in the EST data appears to be
placenta-speci¢c (see Table 1). It should be noted that these
rates of observable tissue speci¢city probably underestimate
the true extent of this phenomenon, since most genes lack
su⁄cient EST sequences (from enough tissues) to detect tissue
speci¢city. Our analysis probably does not detect most real
tissue-speci¢c splicing patterns, simply because of inadequate
EST coverage [55].
What membrane protein functions are speci¢cally modu-
Fig. 2. Production of a soluble protein isoform of syndecan-4 by al-
ternative splicing. A: Gene structure of syndecan-4. Exons are
shown as boxes. The membrane-bound form (SDC4a) uses exon
V-a as the last exon, which codes for the TM domain (white). The
novel soluble form (SDC4b) uses exon V-b as the last exon. B:
Schematic models of syndecan-4 TM regulation. In the normal, full-
length form of syndecan-4, ligand binding to the extracellular do-
main leads to signal transduction by the cytoplasmic domain. In ec-
todomain shedding, proteolytic cleavage of syndecan-4 releases the
ligand binding region from the membrane, which can act as a di¡u-
sible signal or antagonize normal syndecan-4 signaling. Alternative
splicing of syndecan-4 appears to produce a similar soluble form,
which could have similar functional impacts as ectodomain shed-
ding.
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lated by TM domain removal by alternative splicing? To an-
swer this question, we analyzed our 188 candidate gene list
using Gene Ontology (see Section 2 for details). We looked
for GO keywords in the categories of biological-process and
molecular-function which showed signi¢cantly higher represen-
tation in the set of 188 single-TM genes where alternative
splicing removed membrane anchoring than in a control set
consisting of all single-TM genes in ASP (464 genes) (Fig. 3).
Since the control set also consists entirely of genes encoding
TM proteins, this controls for the possibility that a GO term
would receive a strong P-value simply because it is associated
with membrane proteins. Five GO gene categories were en-
riched in the TM removal set with high signi¢cance (P6 0.02,
number of hits in the whole set no less than 15), including:
cell death ; death ; apoptosis ; programmed cell death, response
to external stimulus. Several examples are shown in Table 1,
including BCL2-associated X protein (BAX), BCL2-antago-
nist/killer 1 (BAK1), BCL2-like 1, CD38, and myeloid cell
leukemia sequence 1 (MCL1).
Our results have interesting implications for many experi-
mental studies of the regulation of membrane protein func-
tion. Release of soluble forms of membrane proteins by pro-
teolysis has been shown to be important to the function of
many membrane proteins [25^35]. Since our data indicate that
alternative splicing produces a similar e¡ect in a large number
of membrane proteins (188 found in this study, out of 464
single-pass membrane proteins included in our dataset), we
propose that this phenomenon of ‘TM domain splicing’ may
be another common switching mechanism of regulation of
membrane protein function that deserves further experimental
study. The functional consequences of such alternative splic-
ing events can be either gain of function ^ by releasing func-
tional fragments from the membrane (such as syndecan-4),
mimicking membrane protein proteolysis such as protein ec-
todomain shedding or RIP ^ or simply loss of function due to
disruption of membrane anchorage (such as HLA-DMB). It is
striking that in some cases (e.g. syndecan-4), the production of
a soluble isoform by alternative splicing matches the previ-
ously known proteolytic ectodomain shedding event for that
protein.
As an example of how our database can suggest interesting
directions for new experiments, Table 1 lists a number of
genes that display TM domain splicing. Full lists of our re-
sults will be made available on the web upon publication
(http://www.bioinformatics.ucla.edu/ASAP; for a short vali-
dation, see Appendix 1). In most of these cases, the soluble
isoform produced by alternative splicing is novel (that is, it
has not previously been reported by an mRNA deposited in
GenBank). It has been shown in many cases that releasing
protein domains from membrane anchorage can produce pos-T
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Fig. 3. Gene Ontology keywords which are signi¢cantly enriched or
infrequent among genes in which alternative splicing removed a sin-
gle TM domain, as compared to the set of all single-TM genes in
which alternative splicing was observed.
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itive or negative regulators of the intact membrane-bound
protein forms, or generate protein forms with new function
[33^35]. In some cases it is already possible to infer the func-
tional e¡ect of our novel forms. For example, we have iden-
ti¢ed a novel isoform of HLA-DMB lacking its TM anchoring
region. Coincidentally, it has been reported that an engineered
form of HLA-DMB lacking the TM domain signi¢cantly re-
duces the rate of antigen processing [56]. However, in most
cases new experiments will be required, and in our view the
main value of our database is that it o¡ers experimentalists
many new speci¢c directions for research. It should be useful
for biologists interested in these receptors’ roles (e.g. in
growth control and apoptosis) to design experiments testing
for the presence of these novel protein isoforms and their
functional impact.
In cases where a protein has not previously been shown to
be a membrane protein, biologists should test this experimen-
tally, since our results are based on a prediction method,
TMHMM. This program’s accuracy in predicting TM do-
mains has been reported to be 95.5% [44]. Our independent
tests of TMHMM yielded an accuracy rate of 88% on known
membrane proteins and 96% on known soluble proteins, and
validated the accuracy of TMHMM’s prediction of the
boundaries of TM regions (see Section 2). When we tested a
di¡erent TM prediction method, SOSUI [57], to cross-validate
the results from TMHMM, we obtained very similar results
(the SOSUI dataset indicated conversion of a membrane pro-
tein into a soluble form by alternative splicing in 37.2% of the
genes, versus 40.5% in the TMHMM dataset). Overall, these
data indicate that the pattern of widespread production of
soluble forms through alternative splicing observed in our
dataset is a con¢dent result.
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Table A1
Validation of 10 randomly selected UniGene clusters
UniGene ID Gene description Membrane-bound
form evidence
Soluble-form
evidence
NMD target Matching GenBank/
SwissProt entry
Hs.12330 ectonucleoside triphosphate
diphosphohydrolase 6
mRNA mRNA NO Match
Hs.158200 EGF-like domain, multiple mRNA EST, single NO Shorter in N terminus
Hs.159428 BCL2-associated X protein mRNA mRNA NO YES
Hs.173936 interleukin 10 receptor, beta mRNA EST, single NO Longer in N terminus
Hs.180338 tumor necrosis factor receptor
superfamily, member 25
mRNA mRNA NO Match
Hs.181244 HLA-A mRNA EST, multiple NO Shorter in N terminus
Hs.190488 hypothetical protein
DKFZp66M2411
EST, multiple EST, single soluble form is potential
NMD target
N/A
Hs.2 N-acetyltransferase 2 mRNA EST, single NO Match
Hs.2175 colony-stimulating factor
3 receptor
mRNA mRNA NO Match
Hs.25887 SEMA4 mRNA EST, single soluble form is potential
NMD target
Match
Appendix 1.
Validation of 10 randomly selected genes in our 188 gene list
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